The FDA approved 12 novel medicines in the third quarter of the year (Table 1), an uptick in activity after a slow first half. This apparent acceleration is a recent phenomenon, however, with no first-time green lights awarded in July, and only two in August. The balance came in September, and many will be hoping that this pace is maintained for the rest of the year

Click here to original publication.

Fonte 788 | November 2022 | volume 21 biobusiNess briefs www.nature.com/nrd